These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 37535240)

  • 1. Population pharmacokinetic modeling and dosing simulation of avalglucosidase alfa for selecting alternative dosing regimen in pediatric patients with late-onset pompe disease.
    Tiraboschi G; Marchionni D; Tuffal G; Fabre D; Martinez JM; Haack KA; Miossec P; Kittner B; Daba N; Hurbin F
    J Pharmacokinet Pharmacodyn; 2023 Dec; 50(6):461-474. PubMed ID: 37535240
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Model-Informed Approach Supporting Approval of Nexviazyme (Avalglucosidase Alfa-ngpt) in Pediatric Patients with Late-Onset Pompe Disease.
    Li RJ; Ma L; Drozda K; Wang J; Punnoose AR; Jeng LJB; Maynard JW; Zhu H; Pacanowski M
    AAPS J; 2023 Jan; 25(1):16. PubMed ID: 36653728
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term Safety and Efficacy of Avalglucosidase Alfa in Patients With Late-Onset Pompe Disease.
    Dimachkie MM; Barohn RJ; Byrne B; Goker-Alpan O; Kishnani PS; Ladha S; Laforêt P; Mengel KE; Peña LDM; Sacconi S; Straub V; Trivedi J; Van Damme P; van der Ploeg AT; Vissing J; Young P; Haack KA; Foster M; Gilbert JM; Miossec P; Vitse O; Zhou T; Schoser B;
    Neurology; 2022 Aug; 99(5):e536-e548. PubMed ID: 35618441
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical characteristics and genotypes in the ADVANCE baseline data set, a comprehensive cohort of US children and adolescents with Pompe disease.
    Kishnani PS; Gibson JB; Gambello MJ; Hillman R; Stockton DW; Kronn D; Leslie ND; Pena LDM; Tanpaiboon P; Day JW; Wang RY; Goldstein JL; An Haack K; Sparks SE; Zhao Y; Hahn SH;
    Genet Med; 2019 Nov; 21(11):2543-2551. PubMed ID: 31086307
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety, tolerability, pharmacokinetics, pharmacodynamics, and exploratory efficacy of the novel enzyme replacement therapy avalglucosidase alfa (neoGAA) in treatment-naïve and alglucosidase alfa-treated patients with late-onset Pompe disease: A phase 1, open-label, multicenter, multinational, ascending dose study.
    Pena LDM; Barohn RJ; Byrne BJ; Desnuelle C; Goker-Alpan O; Ladha S; Laforêt P; Mengel KE; Pestronk A; Pouget J; Schoser B; Straub V; Trivedi J; Van Damme P; Vissing J; Young P; Kacena K; Shafi R; Thurberg BL; Culm-Merdek K; van der Ploeg AT;
    Neuromuscul Disord; 2019 Mar; 29(3):167-186. PubMed ID: 30770310
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of avalglucosidase alfa on disease-specific and general patient-reported outcomes in treatment-naïve adults with late-onset Pompe disease compared with alglucosidase alfa: Meaningful change analyses from the Phase 3 COMET trial.
    Toscano A; Pollissard L; Msihid J; van der Beek N; Kishnani PS; Dimachkie MM; Berger KI; DasMahapatra P; Thibault N; Hamed A; Zhou T; Haack KA; Schoser B
    Mol Genet Metab; 2024 Feb; 141(2):108121. PubMed ID: 38184428
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transcriptomic characterization of clinical skeletal muscle biopsy from late-onset Pompe patients.
    Kinton S; Dufault MR; Zhang M; George K
    Mol Genet Metab; 2023 Mar; 138(3):107526. PubMed ID: 36774918
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy, safety profile, and immunogenicity of alglucosidase alfa produced at the 4,000-liter scale in US children and adolescents with Pompe disease: ADVANCE, a phase IV, open-label, prospective study.
    Hahn SH; Kronn D; Leslie ND; Pena LDM; Tanpaiboon P; Gambello MJ; Gibson JB; Hillman R; Stockton DW; Day JW; Wang RY; An Haack K; Shafi R; Sparks S; Zhao Y; Wilson C; Kishnani PS;
    Genet Med; 2018 Oct; 20(10):1284-1294. PubMed ID: 29565424
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of avalglucosidase alfa in individuals with infantile-onset Pompe disease enrolled in the phase 2, open-label Mini-COMET study: The 6-month primary analysis report.
    Kishnani PS; Kronn D; Brassier A; Broomfield A; Davison J; Hahn SH; Kumada S; Labarthe F; Ohki H; Pichard S; Prakalapakorn SG; Haack KA; Kittner B; Meng X; Sparks S; Wilson C; Zaher A; Chien YH;
    Genet Med; 2023 Feb; 25(2):100328. PubMed ID: 36542086
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial.
    Diaz-Manera J; Kishnani PS; Kushlaf H; Ladha S; Mozaffar T; Straub V; Toscano A; van der Ploeg AT; Berger KI; Clemens PR; Chien YH; Day JW; Illarioshkin S; Roberts M; Attarian S; Borges JL; Bouhour F; Choi YC; Erdem-Ozdamar S; Goker-Alpan O; Kostera-Pruszczyk A; Haack KA; Hug C; Huynh-Ba O; Johnson J; Thibault N; Zhou T; Dimachkie MM; Schoser B;
    Lancet Neurol; 2021 Dec; 20(12):1012-1026. PubMed ID: 34800399
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pompe disease in Austria: clinical, genetic and epidemiological aspects.
    Löscher WN; Huemer M; Stulnig TM; Simschitz P; Iglseder S; Eggers C; Moser H; Möslinger D; Freilinger M; Lagler F; Grinzinger S; Reichhardt M; Bittner RE; Schmidt WM; Lex U; Brunner-Krainz M; Quasthoff S; Wanschitz JV
    J Neurol; 2018 Jan; 265(1):159-164. PubMed ID: 29181627
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-life effectiveness 1 year after switching to avalglucosidase alfa in late-onset Pompe disease patients worsening on alglucosidase alfa therapy: A French cohort study.
    Tard C; Bouhour F; Michaud M; Beltran S; Fournier M; Demurger F; Lagrange E; Nollet S; Sacconi S; Noury JB; Magot A; Cintas P; Renard D; Deibener-Kaminsky J; Lefeuvre C; Davion JB; Salort-Campana E; Arrassi A; Taouagh N; Spinazzi M; ; Attarian S; Laforêt P
    Eur J Neurol; 2024 Jul; 31(7):e16292. PubMed ID: 38587143
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population Pharmacokinetic Modeling and Determination of Individual Exposure to Avalglucosidase Alfa in Adolescent and Adult Patients With Late-Onset Pompe Disease: Analysis of Pooled Data From Phase I to III Clinical Trials.
    Tuffal G; Tiraboschi G; Hurbin F; Boittet P; Palmer R; Martinez JM; Fabre D
    Ther Drug Monit; 2023 Oct; 45(5):644-652. PubMed ID: 37556417
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enzyme replacement therapy for infantile-onset Pompe disease.
    Chen M; Zhang L; Quan S
    Cochrane Database Syst Rev; 2017 Nov; 11(11):CD011539. PubMed ID: 29155436
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of antibodies in late-onset Pompe disease: a case series and literature review.
    Patel TT; Banugaria SG; Case LE; Wenninger S; Schoser B; Kishnani PS
    Mol Genet Metab; 2012 Jul; 106(3):301-9. PubMed ID: 22613277
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The new horizons for treatment of Late-Onset Pompe Disease (LOPD).
    Guémy C; Laforêt P
    Rev Neurol (Paris); 2023; 179(1-2):81-89. PubMed ID: 36609019
    [TBL] [Abstract][Full Text] [Related]  

  • 17. White matter lesions in treated late onset Pompe disease are not different to matched controls.
    Schneider I; Hensel O; Zierz S
    Mol Genet Metab; 2019 Jun; 127(2):128-131. PubMed ID: 31153821
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Avalglucosidase alfa: First Approval.
    Dhillon S
    Drugs; 2021 Oct; 81(15):1803-1809. PubMed ID: 34591286
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of cipaglucosidase alfa plus miglustat versus alglucosidase alfa plus placebo in late-onset Pompe disease (PROPEL): an international, randomised, double-blind, parallel-group, phase 3 trial.
    Schoser B; Roberts M; Byrne BJ; Sitaraman S; Jiang H; Laforêt P; Toscano A; Castelli J; Díaz-Manera J; Goldman M; van der Ploeg AT; Bratkovic D; Kuchipudi S; Mozaffar T; Kishnani PS;
    Lancet Neurol; 2021 Dec; 20(12):1027-1037. PubMed ID: 34800400
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-world outcomes from a series of patients with late onset Pompe disease who switched from alglucosidase alfa to avalglucosidase alfa.
    Carter C; Boggs T; Case LE; Kishnani P
    Front Genet; 2024; 15():1309146. PubMed ID: 38313679
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.